Valuation: Natera, Inc.

Market Cap 53.43B 46.58B 43.87B 39.95B 74.91B 5,118B 75B 525B 203B 2,607B 201B 196B 8,413B P/E 2026 *
-272x
P/E 2027 * 50,842x
Enterprise Value 52.35B 45.65B 42.99B 39.15B 73.41B 5,016B 73.5B 515B 198B 2,555B 197B 192B 8,245B EV / Sales 2026 *
18x
EV / Sales 2027 * 14.9x
Free-Float
97.16%
Yield 2026 *
-
Yield 2027 * -
1 day+0.34%
1 week+8.44%
Current month+15.12%
1 month+11.63%
3 months+60.17%
6 months+89.80%
Current year+61.79%
1 week 343.28
Extreme 343.275
373.07
1 month 316
Extreme 316
373.07
Current year 181
Extreme 181
373.07
1 year 157.42
Extreme 157.425
373.07
3 years 36.9
Extreme 36.9
373.07
5 years 26.1
Extreme 26.1
373.07
10 years 7.35
Extreme 7.35
373.07
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap. Importance
9/16/26 Sell

Founder

-3,150 0.0022%
9/16/26 Don

Executive/Senior Manager

-945 0.0007%
9/15/26 Sell

Founder

-52,000 0.0361%
Change 5-day change 1-year change 3-year change Capi.($)
+0.34%+8.44%+104.65%+683.76% 53.25B
+0.09%+1.80%+15.77%+56.47% 26.01B
-0.67%-0.31%-13.30%-36.96% 6.76B
-4.38%-3.74%-4.93%+166.19% 5.98B
+1.24%+0.60%+10.57%+59.01% 3.3B
-3.23%+9.01%-24.52%+2,580.27% 3.02B
-2.51%+5.43%+127.82%+59.10% 2.56B
+17.67%+3.29%+37.89%+47.72% 2.25B
+2.68%+4.66%-6.29%-53.90% 1.91B
+7.47%+20.25%+26.82%-13.76% 1.73B
Average +1.49%+7.20%+27.45%+354.79% 10.68B
Weighted average by Cap. -0.54%+8.21%+58.73%+437.67%

Financials

2026 *2027 *
Net sales 2.91B 2.54B 2.39B 2.18B 4.08B 279B 4.08B 28.61B 11.03B 142B 10.93B 10.69B 458B 3.49B 3.04B 2.87B 2.61B 4.89B 334B 4.9B 34.32B 13.23B 170B 13.11B 12.82B 550B
Net income -192M -168M -158M -144M -269M -18.41B -270M -1.89B -728M -9.38B -722M -706M -30.26B 10.98M 9.57M 9.02M 8.21M 15.4M 1.05B 15.42M 108M 41.62M 536M 41.25M 40.33M 1.73B
Net Debt -1.07B -935M -880M -802M -1.5B -103B -1.5B -10.54B -4.06B -52.31B -4.03B -3.94B -169B -1.4B -1.22B -1.15B -1.05B -1.96B -134B -1.96B -13.75B -5.3B -68.25B -5.25B -5.14B -220B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-09-21 US$370.64 +0.34% 1,969,848
26-09-18 US$369.39 +0.84% 3,718,175
26-09-17 US$366.31 +6.07% 2,561,081
26-09-16 US$345.34 -1.55% 1,432,954
26-09-15 US$350.78 +2.63% 1,775,774
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
370.64USD
Average target price
348.02USD
Spread / Average Target
-6.10%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!